Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Conantokin-Br from Conus brettinghami and selectivity determinants for the NR2D subunit of the NMDA receptor.

Twede VD, Teichert RW, Walker CS, Gruszczyński P, Kaźmierkiewicz R, Bulaj G, Olivera BM.

Biochemistry. 2009 May 19;48(19):4063-73. doi: 10.1021/bi802259a.

2.

Conantokins: peptide antagonists of NMDA receptors.

Layer RT, Wagstaff JD, White HS.

Curr Med Chem. 2004 Dec;11(23):3073-84. Review.

PMID:
15579001
3.

Structure-function relationships of the NMDA receptor antagonist conantokin peptides.

Prorok M, Castellino FJ.

Curr Drug Targets. 2001 Sep;2(3):313-22. Review.

PMID:
11554555
4.

[Advances in study of structures and functions of conantokins].

Feng WH, Zan JB, Zhu YP.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007 Mar;36(2):204-8. Review. Chinese.

PMID:
17443913
5.

Structure-activity studies on alpha-conotoxins.

Muttenthaler M, Akondi KB, Alewood PF.

Curr Pharm Des. 2011 Dec;17(38):4226-41. Review.

PMID:
22204424
6.

Conotoxins: natural product drug leads.

Halai R, Craik DJ.

Nat Prod Rep. 2009 Apr;26(4):526-36. Review.

PMID:
19642420
7.

Structural studies of conotoxins.

Daly NL, Craik DJ.

IUBMB Life. 2009 Feb;61(2):144-50. doi: 10.1002/iub.158. Review.

8.

Neuroprotective and cardioprotective conopeptides: an emerging class of drug leads.

Twede VD, Miljanich G, Olivera BM, Bulaj G.

Curr Opin Drug Discov Devel. 2009 Mar;12(2):231-9. Review.

9.

Strategies for the development of conotoxins as new therapeutic leads.

Brady RM, Baell JB, Norton RS.

Mar Drugs. 2013 Jun 28;11(7):2293-313. doi: 10.3390/md11072293. Review.

Supplemental Content

Support Center